Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

被引：0
作者：
Laura Obici
Senda Ajroud-Driss
Kon-Ping Lin
John L. Berk
Julian D. Gillmore
Parag Kale
Haruki Koike
David Danese
Emre Aldinc
Chongshu Chen
John Vest
David Adams
机构：
[1] IRCCS Fondazione Policlinico San Matteo,Amyloidosis Research and Treatment Centre
[2] Northwestern University Feinberg School of Medicine,Department of Neurology
[3] Taipei Veterans General Hospital,Department of Neurology
[4] Boston Medical Center,National Amyloidosis Centre, Royal Free Hospital
[5] University College London,Department of Neurology
[6] Baylor University Medical Center,Neurology Department
[7] Nagoya University Graduate School of Medicine,undefined
[8] Alnylam Pharmaceuticals,undefined
[9] Université Paris-Saclay,undefined
[10] U1195,undefined
[11] INSERM,undefined
[12] AP-HP,undefined
[13] CHU Bicêtre,undefined
来源：
Neurology and Therapy | 2023年 / 12卷 / 5期
关键词：
ATTRv amyloidosis; hATTR amyloidosis; Nutritional status; Physical function; Polyneuropathy; Quality of life; RNA interference; Vutrisiran;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1759 / 1775
页数：16
相关论文
共 50 条
  • [21] The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
    Yarlas, Aaron
    Lovley, Andrew
    Brown, Duncan
    Vera-Llonch, Montserrat
    Khella, Sami
    Karam, Chafic
    BMC NEUROLOGY, 2023, 23 (01)
  • [22] Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
    David Adams
    Vincent Algalarrondo
    Michael Polydefkis
    Nitasha Sarswat
    Michel S. Slama
    Jose Nativi-Nicolau
    Orphanet Journal of Rare Diseases, 16
  • [23] Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study
    Solomon, Scott D.
    Adams, David
    Kristen, Arnt
    Grogan, Martha
    Gonzalez-Duarte, Alejandra
    Maurer, Mathew S.
    Merlini, Giampaolo
    Damy, Thibaud
    Slama, Michel S.
    Brannagan, Thomas H., III
    Dispenzieri, Angela
    Berk, John L.
    Shah, Amil M.
    Garg, Pushkal
    Vaishnaw, Akshay
    Karsten, Verena
    Chen, Jihong
    Gollob, Jared
    Vest, John
    Suhr, Ole
    CIRCULATION, 2019, 139 (04) : 431 - 443
  • [24] Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR
    Aaron Yarlas
    Andrew Lovley
    Kristen McCausland
    Duncan Brown
    Montserrat Vera-Llonch
    Isabel Conceição
    Chafic Karam
    Sami Khella
    Laura Obici
    Márcia Waddington-Cruz
    Neurology and Therapy, 2021, 10 : 865 - 886
  • [25] Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR
    Yarlas, Aaron
    Lovley, Andrew
    McCausland, Kristen
    Brown, Duncan
    Vera-Llonch, Montserrat
    Conceicao, Isabel
    Karam, Chafic
    Khella, Sami
    Obici, Laura
    Waddington-Cruz, Marcia
    NEUROLOGY AND THERAPY, 2021, 10 (02) : 865 - 886
  • [26] REAL-LIVE EVALUATION OF VUTRISIRAN TREATMENT IN A COHORT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS PATIENTS
    Pernice, Helena
    Kneitz, Ricarda
    Wetzel, Paul
    Fiss, Gunnar
    Kugel, Elias
    Barzen, Gina
    Spethmann, Sebastian
    Messroghli, Daniel
    Wetz, Christoph
    Hahn, Katrin
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S39 - S40
  • [27] Patisiran, an RNAi therapeutic for patients with hereditary transthyretin-mediated amyloidosis: Sub-analysis in Japanese patients from the APOLLO study
    Yamashita, Taro
    Ueda, Mitsuharu
    Koike, Haruki
    Sekijima, Yoshiki
    Yoshinaga, Tsuneaki
    Kodaira, Minori
    Katsuno, Masahisa
    Sobue, Gen
    Zhang, Xiaoping
    White, Matthew T.
    Sweetser, Marianne T.
    Wang, Jing Jing
    Ando, Yukio
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2020, 8 (05): : 251 - 260
  • [28] Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
    Daniel P. Judge
    Arnt V. Kristen
    Martha Grogan
    Mathew S. Maurer
    Rodney H. Falk
    Mazen Hanna
    Julian Gillmore
    Pushkal Garg
    Akshay K. Vaishnaw
    Jamie Harrop
    Christine Powell
    Verena Karsten
    Xiaoping Zhang
    Marianne T. Sweetser
    John Vest
    Philip N. Hawkins
    Cardiovascular Drugs and Therapy, 2020, 34 : 357 - 370
  • [29] Responder analysis for neuropathic assessments in patients with hereditary transthyretin amyloidosis with polyneuropathy
    Yarlas, Aaron
    Lovley, Andrew
    Vera-Llonch, Montserrat
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 478 - 478
  • [30] Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study
    Lin, Kon-Ping
    Yang, Chih-Chao
    Lee, Yi-Chung
    Lee, Ming-Jen
    Vest, John
    Sweetser, Marianne T.
    White, Matthew T.
    Badri, Prajakta
    Hsieh, Sung-Tsang
    Chao, Chi-Chao
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2024, 123 (09) : 975 - 984
12345